CA2692773A1 - Procedes de modification d'oligomeres amyloides .beta. au moyen de composes non peptidiques - Google Patents

Procedes de modification d'oligomeres amyloides .beta. au moyen de composes non peptidiques Download PDF

Info

Publication number
CA2692773A1
CA2692773A1 CA 2692773 CA2692773A CA2692773A1 CA 2692773 A1 CA2692773 A1 CA 2692773A1 CA 2692773 CA2692773 CA 2692773 CA 2692773 A CA2692773 A CA 2692773A CA 2692773 A1 CA2692773 A1 CA 2692773A1
Authority
CA
Canada
Prior art keywords
formation
compound
addls
less
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2692773
Other languages
English (en)
Inventor
Grant A. Krafft
Todd Pray
William F. Goure
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acumen Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2692773A1 publication Critical patent/CA2692773A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
CA 2692773 2007-07-12 2007-07-12 Procedes de modification d'oligomeres amyloides .beta. au moyen de composes non peptidiques Abandoned CA2692773A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/073408 WO2009008890A1 (fr) 2007-07-12 2007-07-12 PROCÉDÉS DE MODIFICATION D'OLIGOMÈRES AMYLOÏDES β AU MOYEN DE COMPOSÉS NON PEPTIDIQUES

Publications (1)

Publication Number Publication Date
CA2692773A1 true CA2692773A1 (fr) 2009-01-15

Family

ID=39205308

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2692773 Abandoned CA2692773A1 (fr) 2007-07-12 2007-07-12 Procedes de modification d'oligomeres amyloides .beta. au moyen de composes non peptidiques

Country Status (5)

Country Link
EP (1) EP2170322B1 (fr)
CA (1) CA2692773A1 (fr)
ES (1) ES2401664T3 (fr)
MX (1) MX2010000368A (fr)
WO (1) WO2009008890A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (fr) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Méthode de traitement d'amyloïdoses
US9006283B2 (en) 2007-07-12 2015-04-14 Acumen Pharmaceuticals, Inc. Methods of modifying amyloid β oligomers using non-peptidic compounds
US8962677B2 (en) 2007-07-12 2015-02-24 Acumen Pharmaceuticals, Inc. Methods of restoring cognitive ability using non-peptidic compounds
US9217024B2 (en) 2007-12-18 2015-12-22 Acumen Pharmaceuticals, Inc. ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
CA2796339C (fr) 2010-04-15 2020-03-31 Abbott Laboratories Proteines de liaison a la beta amyloide
EP3533803B1 (fr) 2010-08-14 2021-10-27 AbbVie Inc. Anticorps anti-bêta-amyloïde

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20100029773A1 (en) * 2004-05-24 2010-02-04 Ludwig-Maximilians-Universitat Munchen Systematic identification of new anti-prion drugs by high-throughput screening based on scanning for intensely fluorescent targets (sift)
CA2652449A1 (fr) * 2006-05-19 2007-11-29 Waratah Pharmaceuticals Inc. Procedes de criblage pour modulateurs de beta-amyloide

Also Published As

Publication number Publication date
ES2401664T3 (es) 2013-04-23
EP2170322B1 (fr) 2013-02-13
MX2010000368A (es) 2010-07-02
WO2009008890A1 (fr) 2009-01-15
EP2170322A1 (fr) 2010-04-07

Similar Documents

Publication Publication Date Title
EP2170322B1 (fr) PROCÉDÉS DE MODIFICATION D'OLIGOMÈRES AMYLOÏDES ß AU MOYEN DE COMPOSÉS NON PEPTIDIQUES
CA2692775C (fr) Procedes d'amelioration de la fonction cognitive en utilisant des composes non peptidiques
US8962677B2 (en) Methods of restoring cognitive ability using non-peptidic compounds
US9968618B1 (en) Combination therapies for the treatment of Alzheimer's disease and related disorders
EP2560624B1 (fr) Formulation thérapeutique visant à réduire les effets secondaires de médicaments
US8563615B2 (en) Use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders
US20110098309A1 (en) Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds
KR20080056731A (ko) 인지 기능의 개선을 위한 로시글리타존 및 도네페질의조합물
US20100152125A1 (en) Compositions And Methods For The Diagnosis, Treatment, And Prevention Of Amyotrophic Lateral Sclerosis And Related Neurological Diseases
WO2009009768A2 (fr) Procédés consistant à inhiber la formation de ligands diffusables d'amyloide-b utilisant des composés d'acylhydrazide
JP2018076332A (ja) （３ａＲ）−１，３ａ，８−トリメチル−１，２，３，３ａ，８，８ａ−ヘキサヒドロピロロ［２，３−ｂ］インドール−５−イルフェニルカルバメートの有効量およびその使用方法
JP2023516284A (ja) カンナビジオールの組成物および治療的使用
US9006283B2 (en) Methods of modifying amyloid β oligomers using non-peptidic compounds
US10668032B2 (en) Use of lithium benzoate for treating central nervous system disorders
US7381733B2 (en) Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases
JP5713990B2 (ja) ２型糖尿病治療用の医薬組成物
RU2461377C2 (ru) Способ улучшения когнитивной функции (варианты)
WO2010137681A1 (fr) Agent prophylactique ou thérapeutique pour maladies rétiniennes comprenant du tranilast, méthode de prévention ou de traitement de maladies rétiniennes, tranilast ou sel pharmaceutiquement acceptable de celui-ci, et utilisation de ceux-ci
RU2448694C2 (ru) Cпособ противодействия образованию нейротоксичных белков addl (варианты), способ модуляции нейрональной дисфункции или нейротоксичности посредством непептидного соединения и композиция (варианты) на его основе
HRP20000860A2 (en) Methods for reducing levels of homocysteine and c-reactive protein
WO2022247834A1 (fr) Composé cinnamamide substitué anxiolytique et antidépresseur
JP2021520412A (ja) タンパク質ミスフォールディング疾患のための療法
NZ733926A (en) Salt of a pyrimido[6,1-a]isoquinolin-4-one compound
NZ733926B2 (en) Salt of a pyrimido[6,1-a]isoquinolin-4-one compound

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20151124